louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00966745: Milrinone During Living Donor Hepatectomy
Official title: Effect of Milrinone During Living Donor Hepatectomy Using a Low Central Venous Pressure Technique
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatectomy
Keywords: surgical field condition
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2009-08-27
Enrollment: 38
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Maintaining a low central venous pressure during living donor hepatectomy is routine practice. The investigators tried to test the hypothesis that using milrinone to maintain a low central venous pressure (CVP) during is associated with a superior surgical field and less blood loss.


Eligibility criteria: Inclusion Criteria:

* Living liver donors

Exclusion Criteria:

* Donors with concurrent cardiac, pulmonary, and urologic disease
* Hepatectomy performed laparoscopically

Primary outcomes:
measure: condition of surgical field
timeFrame: intraoperative period (from the start of surgery to end of living donor hepatectomy)
Secondary outcomes:
measure: the use of vasopressor and diuretics to maintain hemodynamic stability and low CVP status, respectively
timeFrame: intraoperative period (from the start of surgery to end of living donor hepatectomy)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT00817245: Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR)
Official title: Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Central Serous Chorioretinopathy
Keywords: CSR
Helicobacter pylori
Lead sponsor: Tabriz University
Sponsor class: OTHER
First posted: 2009-01-06
Enrollment: 50
Sex: ALL
Minimum age (years): 28
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Etiology of ICSCR is not known however recent studies regard the role of immunologic and infectious processes in the pathogenesis of ICSCR.one of these hypothesis is the role of helicobacter pylori in the pathogenesis of ICSCR so perhaps treatment of h pylori have positive effect on the remission of ICSCR.

Detailed description: we will choose 50 cases of patients with ICSCR who are infected with h.pylori.25 cases will receive anti h.pylori regiment and 25 cases as controls will receive no medication.then we will compare the time of submacular fluid resorption and macular thickness and visual acuity among these two groups.

Eligibility criteria: Inclusion Criteria:

* the persons who are infected with helicobacter pylori and have ICSCR

Exclusion Criteria:

* history of previous eye surgery ,to have indication of laser therapy,corticosteroid therapy,pregnancy,

Primary outcomes:
measure: Subretinal fluid level
Secondary outcomes:
measure: time of sub macular fluid absorption
Other outcomes:
Locations:
city: Tabriz
country: Iran, Islamic Republic of
facility: Alireza JavadzadehTabriz
Study officials:
affiliation: Alireza Javadzadeh
name: Alireza Javadzadeh
role: STUDY_CHAIR
References:
Clinical trial NCT03848247: The Effect of Experimental Neck Pain in Healthy Participants
Official title: The Effect of Experimental Neck Pain in Healthy Participants - The Transition From Acute to Ongoing Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Neck Pain
Lead sponsor: Aalborg University
Sponsor class: OTHER
First posted: 2019-02-20
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigates if/how an experimentally applied muscle pain/soreness, lasting for some days may affect brain activity, balance, movement patterns, muscle function and pain sensitivity in a healthy population

Detailed description: All included healthy volunteers will participate in test-sessions on 4 separate days over approximately 2 weeks.

During the study participants will be randomised into and either a control group (injection of isotonic saline into a neck muscle) or neck pain group (injection of Nerve Growth Factor (NGF) into a neck muscle).

Alle participants tested with regards to:

Brain activity related to neck muscles will be estimated using TMS Balance will be tested using a force place Body movements will be recorded using 3D tracking Muscle activity will be estimated using electromyography (EMG)

Eligibility criteria: Inclusion Criteria:

* Healthy men and women aged 18-50 years
* Only for sub-projects 1 and 2: Right-handed
* Able to speak, read and understand Danish and English

Exclusion Criteria:

* Pain from the neck or shoulder area during the past 6 months
* Experience of delayed onset muscle soreness (DOMS) during the week leading up to the test session
* Former surgery in neck or shoulder
* Current or previous chronic or recurrent pain condition
* Pregnancy
* Drug addiction defined as the use of cannabis, opioids or other drugs
* Previous neurologic, musculoskeletal or mental illnesses
* Regular use of analgesics
* Abnormally disrupted sleep in the last 24 hours preceding the experiment
* Lack of ability to cooperate
* Unable to pass the TASS safety screening questionnaire for TMS

Primary outcomes:
measure: Change in pressure pain threshold (PPT) measured with a handheld pressure algometer
timeFrame: Day 0, 2,4 and 15
measure: Change in motor evoked potentials
timeFrame: Day 0, 4 and 15
measure: Change in Body movement
timeFrame: Day 0, 4 and 15
Secondary outcomes:
measure: Change in muscle activity (EMG)
timeFrame: Day 0, 4 and 15
measure: Change in standing balance
timeFrame: Day 0, 4 and 15
measure: Change in perceived pain: McGill Pain Questionnaire
timeFrame: Day 0, 2,4 and 15
measure: Disability
timeFrame: Day 0, 2,4 and 15
measure: Pain Catastrophizing Scale (13 item questionnaire)
timeFrame: Day 2
measure: The Big Five Inventory (BFI)
timeFrame: Day 2
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Dept. Of Health Science and Technology, SMI, Aalborg University
Study officials:
affiliation: Aalborg University
name: Steffan W Christensen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01570647: Automated Connective Tissue Torque Sensor
Official title: Automated Connective Tissue Torque Sensor
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Connective Tissue
Musculoskeletal Pain
Lead sponsor: Stromatec, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Center for Complementary and Integrative Health (NCCIH)
First posted: 2012-04-04
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: community sample

Brief summary: The purpose of this study is to develop a measure - the needle torque test - capable of detecting connective tissue abnormalities associated with musculoskeletal disorders.

Detailed description: Chronic musculoskeletal pain is a source of considerable disability, work absenteeism and health care costs. A major obstacle to the treatment of these conditions is the lack of methods to objectively assess connective tissues and measure the effect of treatments. Needle torque test technology under development in this project will potentially enable objective measurement of connective tissue abnormalities associated with musculoskeletal pain and dysfunction. This could help evaluate the efficacy of various treatments and enhance the objective monitoring of patient progress in clinical practice.

Eligibility criteria: Inclusion Criteria for chronic low back pain subjects:

* back pain that has disrupted activity for more than half the days in the past 12 months.

Inclusion Criteria for restricted hamstring subjects:

* 90/90 test of more than 20 degrees

Inclusion Criteria for systemic scleroderma subjects:

* physician diagnosis

Inclusion criteria for joint hyperlaxity subjects:

* Beighton test score of 7 or higher

Exclusion Criteria for all subjects:

* surgery or scars in thighs or low back
* neurological or major psychiatric disorder
* bleeding disorders
* acute systemic infection
* pregnancy

Primary outcomes:
measure: Number of needle revolutions to achieve threshold torque
timeFrame: Time zero, 30 minutes and one week
Secondary outcomes:
Other outcomes:
Locations:
city: Burlington
country: United States
facility: Stromatec, Inc.
state: Vermont
Study officials:
affiliation: Stromatec, Inc.
name: Robert Davis
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02359747: Analysis of Human Genomic DNA in Embryo's Culture Media
Official title: Analysis of Human Genomic DNA in Embryo's Culture Media Targeting on a Single Gene Disease and Point Mutations
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Single-Gene Disease
Keywords: free gDNA
culture media
Lead sponsor: Cervesi Hospital, Cattolica, Italy
Sponsor class: OTHER
First posted: 2015-02-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all the mediun descarted after embryos culture in vitro

Brief summary: try to find genomic DNA in culture medium after the embryos develop on Day 3 and Day 5 also in single step culture media. using direct PCR Polymerase Chain Reaction and also WGA Whole Genome Amplification before PCR and sequencing of the samples to find the point mutation

Detailed description: Human fertilized oocytes were individually cultured from Day 1 to Day 3, and from day 3 to days 5/6, in 10 ul medium. A total of 100 samples (50 spent media from Day 3 and 50 from Day 5/6) will be use in the study.

Double-stranded DNA (dsDNA) amplifiability will be evaluated in embryos culture media by quantitative PCR on a multicopy gene target (TBC1D3). Quantification will be made with a standard curve constructed with genomic DNA (with culture media -day 3 and day5-, to take into account media inhibitory effects) TSPY1 amplification will be use to assess the presence of Y chromosome WGA followed by PCR on a single copy gene (MTHFR gene) will be performed on a subset of some samples to monitor the C677T polymorphism (genotyping by sequencing) WGA followed by PCR on a single copy gene (MTHFR) will be also performed on blastocoele fluids

Eligibility criteria: Inclusion Criteria

* all the patients undergoing IVF treatment at Cervesi Hospital

Exclusion Criteria:

* patients with embryos that can't be cultured from day 0 (insemination day) to day 5/6 (blastocyst stage)

Primary outcomes:
measure: genomic DNA in culture medium (pg)
timeFrame: 1 year
Secondary outcomes:
measure: amplification of point mutation
timeFrame: 1 year
Other outcomes:
Locations:
city: Cattolica
country: Italy
facility: Cervesi Hospital
city: Cattolica
country: Italy
facility: cervesi Hospital
Study officials:
References:
Clinical trial NCT00897247: Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
Official title: Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malignant Mesothelioma
Pulmonary Complications
Keywords: malignant mesothelioma
pulmonary complications
Lead sponsor: Barbara Ann Karmanos Cancer Institute
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2009-05-12
Enrollment: 494
Sex: ALL
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Clinic

Brief summary: RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking for biomarkers to detect mesothelioma early in patients exposed to asbestos or vermiculite.

Detailed description: OBJECTIVES:

* Identify patients with known asbestos exposure at early stages of disease development (i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural mesothelioma).
* Determine the expression levels of tumor-associated proteins in these patients.
* Analyze samples of serum and pleural effusions obtained from these patients.
* Determine the proteomic profile of samples obtained from these patients.
* Determine the molecular mechanisms associated with the regulation of the extracellular matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix metalloproteins) involved in disease onset and progression.

OUTLINE: This is a multicenter study.

Patients undergo collection of body cavity fluid, including pleural effusion, and blood. Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available, are analyzed for proteomic profile, gene expression profile, and tumor-associated protein expression levels.

PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Exposure to vermiculite or asbestos insulation

  * Symptomatic or nonsymptomatic exposure-related disease
* Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases
timeFrame: At time of analysis
Secondary outcomes:
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Institute
state: Michigan
Study officials:
affiliation: Barbara Ann Karmanos Cancer Institute
name: Anil Wali, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00798447: Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery
Official title: A Prospective, Randomized, Double Blind Study to Compare the Efficacy and Safety of a n-3 Fatty Acid-containing Lipid Emulsion During Parenteral Nutrition in Patients Considered for Major Surgery for Gastric and Colorectal Cancer.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: GI Cancer
Keywords: post OP
Lead sponsor: B. Braun Melsungen AG
Sponsor class: INDUSTRY
Collaborators: name: B.Braun Taiwan Co., Ltd.
First posted: 2008-11-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of the impact of peri- and post-operative parenteral nutrition enriched with n-3 PUFA on post-operative inflammatory processes.


Eligibility criteria: Inclusion Criteria:

* Patients considered for major surgery for gastric and colorectal cancer
* expected requirement for post operative PN or TPN of at least 7 days
* possibility of PN/TPN provision 1 day prior to surgery
* Age \>18 years old and \<80 years old
* Hemodynamically stable
* Written Informed consent

Exclusion Criteria:

* Participation in a clinical study with an investigational drug or an investigational medical device within one month prior to the start of study
* Patients with sepsis, severe sepsis or septic shock
* Known or suspected drug abuse
* Intrahepatic cholestasis
* General contraindications for infusion therapy such as acute pulmonary edema, hyperhydration and decompensated cardiac insufficiency
* Pregnancy (positive in urine) or lactation
* Autoimmune disease e.g. HIV
* Known hypersensitivity to egg-, soy-, and fish proteins or any of the ingredients of the investigational products
* Hemodynamic failure of any origin (hemorrhagic shock, myocardial infarction, cardiac failure)
* Alterations of coagulation (thrombocytes \<150000 /mm3), PT \< 50%, PTT \> 40 sec
* Ketoacidosis caused by Diabetes mellitus within 7 days prior to onset of study
* Renal insufficiency with serum creatinine \> 1.4 mg/dL (\>124 µmol/L)
* Patients with severe liver dysfunction with bilirubin \>2.5 mg/dL (\> 43 µmol/L)
* Lipid disorders, in particular fasting serum triglycerides \> 250 mg/dL (\>2.85 mmol/L),

Primary outcomes:
measure: reduction of pro inflammatory activity
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital Taipei
Study officials:
References:
citation: Ma CJ, Wu JM, Tsai HL, Huang CW, Lu CY, Sun LC, Shih YL, Chen CW, Chuang JF, Wu MH, Wang MY, Lin MT, Wang JY. Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patients. Nutr J. 2015 Jan 21;14:9. doi: 10.1186/1475-2891-14-9.
Clinical trial NCT00750347: Antagonistic Interaction CB1-paracetamol
Official title: Evaluation of the Interaction of Rimonabant (Antagonist of CB1 Receptor) on the Analgesic Effect of Paracetamol in Intravenous Administration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pain
Keywords: pain,
analgesia
Healthy volunteers
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2008-09-10
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Evaluation of an possible inhibiting effect of Rimonabant on the analgesic effect of Paracetamol in healthy volunteers

Detailed description: Double Blind, cross-over, randomized and controlled versus placebo, study in healthy volunteers.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* between 18 and 40 years old
* written consent given

Exclusion Criteria:

* Rimonabant or paracetamol hypersensibility
* Excessive consumption of alcohol, tobacco, coffee, tea or toxicomania
* Concomitant medication
* Chronical diseases

Primary outcomes:
measure: Pain's threshold with electrical stimulation (Pain Matcher). Pain's threshold with mechanical stimulation (electronical Von Frey).
timeFrame: during electrical stimulation
Secondary outcomes:
measure: Plasmatic concentration of paracetamol or his metabolite with or without Rimonabant
timeFrame: with or without rimonabant
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CIC-CPC
city: Clermont-Ferrand
country: France
facility: CHU Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Dubray Claude, Pr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04275947: The COVID-19 Mobile Health Study (CMHS)
Official title: The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Lead sponsor: Chinese Alliance Against Lung Cancer
Sponsor class: OTHER
Collaborators: name: Shanghai Respiratory Research Institution
First posted: 2020-02-19
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: -High risk of COVID-19

Brief summary: This study evaluates a brand-new cell phone-based auto-diagnosis system, which is based on the clinical guidelines, clinical experience, and statistic training model. We will achieve secure and 1st hand data from physicians in Wuhan, which including 150 cases in the training cohort and 300 cases in the validation cohort.


Eligibility criteria: Inclusion Criteria:

* High risk of COVID-19
* RT-PCR test result of SAR2-CoV-19

Exclusion Criteria:

* Not available for RT-PCR test result of SAR2-CoV-19

Primary outcomes:
measure: Accuracy of nCapp COVID-19 risk diagnostic model
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
Study officials:
affiliation: Shanghai Respiratory Research Institution
name: Chunxue Bai
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yang D, Zhang X, Powell CA, Ni J, Wang B, Zhang J, Zhang Y, Wang L, Xu Z, Zhang L, Wu G, Song Y, Tian W, Hu JA, Zhang Y, Hu J, Hong Q, Song Y, Zhou J, Bai C. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study. Cancer. 2018 Jan 15;124(2):262-270. doi: 10.1002/cncr.31020. Epub 2017 Sep 20.
Clinical trial NCT06877247: A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Official title: A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Secondary Hyperparathyroidism
Lead sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-03-14
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] SHR6508.


Eligibility criteria: Inclusion Criteria:

1. Be able and willing to provide a written informed consent form.
2. Male subjects and postmenopausal women.
3. Meet the Body Mass Index (BMI) standard.

Exclusion Criteria:

1. Subjects with a history of cardiovascular diseases.
2. Subjects with gastrointestinal diseases.
3. Subjects with a history of surgery.
4. Subjects with a history of blood loss.
5. Abnormal blood pressure.
6. Be allergic to a drug ingredient or component.
7. Subject with a history of alcohol abuse and drug abuse
8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.

Primary outcomes:
measure: Cumulative excretion of radioactivity
timeFrame: Day 1 to Day 168.
measure: Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)
timeFrame: Day 1 to Day 6.
Secondary outcomes:
measure: Adverse Events (AEs)
timeFrame: About 24 weeks.
measure: Serious adverse Events (SAEs)
timeFrame: About 24 weeks.
Other outcomes:
Locations:
city: Jinan
country: China
facility: The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province)
state: Shandong
Study officials:
References: